|
 |
CetrotideThis page contains recent news articles, when available, and an overview of Cetrotide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Cetrotide (when available) Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Mechanism Of Action: Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. News Articles on Cetrorelix Sanofi-Aventis: near-term benign prostatic hyperplasia prospects look bleak - Dec 21, 2009 The product is available on the market for the treatment of infertility under the brand name Cetrotide, attaining relatively modest global sales of $32m in ... Trading Markets (press release) EMD Serono film contest flags infertility - Nov 9, 2009 EMD Serono's fertility products include recombinant versions of three hormones – Gonal-f, Ovidrel and Luveris – along with Cetrotide, which is used to ... Medical Marketing and Media AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results - Nov 11, 2009 Additionally, sales volumes of Cetrotide(R) were lower during the three-month period ended September 30, 2009, compared to the same period in 2008. ... CNNMoney.com (press release) Æterna Zentaris diminue sa perte - Nov 11, 2009 De plus, le volume des ventes de Cetrotide a été moins élevé au cours de la période de trois mois terminée le 30 septembre 2009, comparativement à la ... Le Journal de Québec AEterna Zentaris Gains Market Approval for Cetrotide (cetrorelix) in... - Apr 20, 2006 QUEBEC CITY, CANADA -- April 20, 2006 -- AEterna Zentaris Inc. today announced it gained market approval for Cetrotide® (cetrorelix) in Japan for in vitro ... DG News AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5... - Nov 12, 2008 QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine ... Genetic Engineering News - Genetic Engineering News (press release) cetrorelix AEterna Zentaris planning phase III program.(Pharmaceutical... - Mar 7, 2005 New York, USA, Gilles Gagnon, President & CEO of AEterna Zentaris, provided R&D focus with an update on the development of cetrorelix (CETROTIDE), ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones AEterna Zentaris loss triples on unit spinoff - Aug 15, 2007 The revenue increase came from sales of Cetrotide, used in in-vitro fertilization, and Impavido, a drug for leishmaniasis, also known as black fever, ... Toronto Star Aeterna shares slump on drug trial - Mar 5, 2007 Used under the trade name Cetrotide for in-vitro fertilization, trials are being conducted to use Cetrorelix for the treatment of abnormal benign growth of ... Toronto Star Press Release: AEterna Zentaris Launches Cetrotide(R) (cetrorelix) in... - Sep 21, 2006 AEterna Zentaris Launches Cetrotide(R) (cetrorelix) in Japan for In Vitro Fertilization. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … Update; Aeterna Zentaris launches Cetrotide (cetrorelix) in Japan... - Oct 16, 2006 2006 OCT 16 - (NewsRx.com) -- Aeterna Zentaris, Inc., (AEZ; AEZS) announced that Cetrotide (cetrorelix) has been launched in Japan for in vitro ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones … Release: AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty... - Nov 12, 2008 AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Shionogi, Nippon Kayaku to Release Cetrotide. - Sep 21, 2006 Tokyo, Japan, Sept 21, 2006 - (JCN) - Shionogi & Co., Ltd. and Nippon Kayaku Co., Ltd. today announced the release of Cetrotide (generic name: Cetrorelix ... Free with registration - JCNN News Summaries - AccessMyLibrary.com … Release: AEterna Zentaris Closes Sale of Cetrotide(R) Royalty... - Dec 3, 2008 AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Ovulation - Shionogi, Nippon Kayaku Receive Approval For Cetrotide - Apr 23, 2006 Cetrotide (cetrorelix acetate), which was developed by German company Zentaris AG, ... Through the introduction of Cetrotide, the two companies aim to ... Medical News Today - Medical News Today (press release) Canada biotech: AEterna Zentaris gets US$52.5m from Cetrotide - Nov 20, 2008 After selling a building, a marketed product and a subsidiary during the past year, AEterna Zentaris Inc. continued its asset monetization strategy by ... $34.00 - EIU Country Analysis - Alacra Store AEterna Zentaris Reclaims Cetrorelix Rights for All Indications - May 8, 2007 Marketed under the brand name Cetrotide®, cetrorelix is approved for therapeutic use as part of in vitro fertilization programs in Europe, the US, ... Genetic Engineering News - Genetic Engineering News (press release) … Kayaku, Shionogi Release Cetrotide, Premature Ovulation Inhibitor,... - Sep 21, 2006 Canadian biopharmaceutical company AEterna Zentaris, through German subsidiary Zentaris GmbH, is the worldwide licensor of development rights for Cetrotide, ... Free with registration - JCNN News Summaries - AccessMyLibrary.com Shionogi, Nippon Kayaku To Release Cetrotide In Japan - Sep 23, 2006 Shionogi & Co., Ltd. and Nippon Kayaku Co., Ltd. today announced the release of Cetrotide (generic name: Cetrorelix acetate), indicated for the prevention ... Medical News Today - Medical News Today (press release) … : AEterna Zentaris Gains Market Approval for Cetrotide(R) (cetroreli... - Apr 20, 2006 AEterna Zentaris Gains Market Approval for Cetrotide(R) (cetrorelix) in Japan for In Vitro Fertilization. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … , Inc. Aeterna Zentaris gains market approval for Cetrotide in... - May 15, 2006 Aeterna Zentaris obtained an undisclosed milestone payment from its partners and will receive revenues from the supply of Cetrotide (cetrorelix) to its ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones … Regulatory Review Period for Purposes of Patent Extension; CETROTIDE... - Jun 9, 2006 FDA recently approved for marketing the human drug product CETROTIDE ... CETROTIDE is indicated for the inhibition of premature luteinizing hormone surges ... Pay-Per-View - Federal Register - Factiva, from Dow Jones International Approvals: Omnitrope, Prograf, Cetrotide - May 1, 2006 May 1, 2006 — The European Commission has approved a generic formulation of somatropin for use as long-term replacement therapy in children and adults, ... Medscape SSK'lıya tüp bebek müjdesi - Nov 16, 2005 Tüp bebek uygulaması öncesinde 'cetrotide', 'ovitrelle', 'luveris' gibi ilaçlar kullanılacaksa miktarı belirtilecek ve bunlar kadın hastalıkları-doğum uzman ... Radikal Aeterna Zentaris vend des droits pour 52,5 M$ - Nov 12, 2008 Les droits d'Aeterna Zentaris sur son produit Cetrotide sont actuellement ... Cetrotide (cetrorelix) est administré aux femmes pour prévenir l'ovulation ... LesAffaires.com - LesAffaires.com Æterna Zentaris enregistre une perte de 4,8 million - Aug 15, 2007 L'utilisation de Cetrotide est indiquée pour la stimulation contrôlée en fécondation in vitro. Impavido est, pour sa part, le premier médicament oral ... Le Devoir - Le Devoir (Abonnement) Serono Falls As Buyers Fail to Materalize MOVERS MARKETPLACE By … - Jan 25, 2006 Serono's fastest-growing products are the psoriasis medicine Raptiva, the ovulation hormone Ovidrel, the ovulation control hormone Cetrotide, ... RedOrbit AEterna Zentaris cherche un partenaire - May 7, 2008 L'augmentation des produits est essentiellement attribuable à une hausse des ventes de Cetrotide à Merck Serono, compensée principalement par une baisse des ... Matinternet Cetrotide und Ovitrelle - Adeba.de - Das große Forum für alle Eltern... - Jan 26, 2008 Hallo zusammen, habe mal ne dringende Frage. Muss heute Abend um 23 Uhr mit Ovitrelle den Eisprung auslösen. Am Montag ist Punktion. ... Adeba.de AEterna Zentaris va commercialiser le produit Cetrotide au Japon - Apr 20, 2006 La société AEterna Zentaris (AEZ) a annoncé jeudi qu'elle avait obtenu l'approbation pour la mise en marché au Japon de son produit Cetrotide pour la ... Canoë AEterna Zentaris Inc acquires Echelon Biosciences Inc - Deal Snapshot... - Jan 6, 2005 Trial Details September ##, #### Aeterna Zentaris Inc. anno unced that Cetrotide… AETERNA ZENTARIS INC-DRUG PIPELINE ANALYSIS · AETERNA ZENTARIS INC-DRUG ... Pay-Per-View - deals - Alacra Store AEterna Zentaris Reports Third Quarter 2007 Financial and Operating … - Nov 7, 2007 The sales of Cetrotide(R) were lower for the three-month period ended September 30, 2007 compared to the same period in 2006, due to a significant first ... $4.95 - PR Newswire - ECNext Press Release: World fertility experts to meet in Montreal - IVF and... - Sep 12, 2007 Cetrotide ... antagonist treatment approved for in vitro fertilization. ... Article: AEterna Zentaris Gains Market Approval for Cetrotide(R) ... ... Pay-Per-View - PR Newswire - HighBeam Research Suit opposes Medicare denials of off-label, non-compendia drugs - Jan 21, 2008 But in this case, the prescribed use of Cetrotide is not only absent from Food ... "The evidence clearly establishes that the use of Cetrotide to treat the ... American Medical News Press Release: AEterna Zentaris Reports Third Quarter 2008 Financial ... - Nov 13, 2008 In addition, contingent on 2010 net sales of Cetrotide(R) reaching a specified level, AEterna Zentaris would receive an additional payment of $2.5 million ... Pay-Per-View - PR Newswire - HighBeam Research La stratégie des petits pas d'Æterna - Nov 29, 2008 Le Cetrorelix a un potentiel 15 fois plus grand que le Cetrotide, ... Dans le cas du Cetrotide, on parle d'un marché de 80 millions alors que celui du ... LesAffaires.com - LesAffaires.com AEterna Zentaris Receives First Regulatory Approval for Impavido(R)... - Mar 23, 2005 With two products on the market generating revenues, Cetrotide(R) and Impavido(R), we are further establishing a solid financial basis to support the ... Free with registration - PR Newswire - AccessMyLibrary.com NEW PRODUCTS - Oct 2, 2006 Zentaris GmbH of Germany holds worldwide development rights to Cetrotide. ... Cetrotide is the first GnRH antagonist to receive approval in Japan. ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones AEterna Zentaris Receives First Regulatory Approval for Impavido(R)... - Mar 30, 2005 With two products on the market generating revenues, Cetrotide(R) and Impavido(R), we are further establishing a solid financial basis to support the ... Free with registration - PR Newswire Europe - AccessMyLibrary.com Federal Court Suit Filed To Lift Medicare Coverage Bar On Off-Label,... - Nov 27, 2007 She had a recurrence in 1987, and has been taking Cetrotide, a commonly prescribed medication, since 1999 to treat and limit her cancer. ... Medical News Today - Medical News Today (press release) FINAL TRANSCRIPT - May 7, 2008 The decrease is related to the Cetrotide sales, ex Japan, by ... related to a high concentration of Cetrotide with a formulation that is more costly. ... $54.00 - Thomson StreetEvents - Alacra Store PotashCorp pays 10 cents - Nov 13, 2008 In 2000 Aeterna granted Europe's Merck Serono exclusive rights to market its Cetrotide product for in-vitro fertilization worldwide, except Japan. ... Canada.com Suit Filed to Lift Medicare Ban on Off-Label but 'Necessary Drugs' - Nov 26, 2007 She had a recurrence in 1987, and has been taking Cetrotide, a commonly prescribed medication, since 1999 to treat and limit her cancer. ... SeniorJournal.com AEterna Zentaris Reports 2006 Second Quarter Results. - Aug 11, 2006 ..."During the second quarter, we made great strides in advancing our products through the pipeline at all stages as exemplified by Cetrotide(R)'s marketing ... Free with registration - PR Newswire - AccessMyLibrary.com cetrorelix Solvay clinical data (phase II) (endometriosis).(Brief... - Mar 28, 2005 Solvay has decided to undertake phase III development of AEterna Zentaris' third-generation GnRH antagonist cetrorelix (CETROTIDE) for the treatment of ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones AEterna Zentaris Reports Second Quarter 2007 Financial and Operating ... - Aug 14, 2007 The decrease in loss from operations is attributable to increased sales of Cetrotide(R) and Impavido(R) partly offset by additional expenses in R&D. ... Free with registration - PR Newswire - AccessMyLibrary.com A New Era at AEterna - May 24, 2007 In addition, Cetrotide is the currently marketed version of cetrorelix that is ... Cetrotide provides the company with royalties to fund research and ... fool.com Press Release: AEterna Zentaris Reports 2006 First Quarter Financial ... - May 3, 2006 Recent Events - Gained market approval for Cetrotide(R) (cetrorelix) in Japan for in vitro ... Operating Officer at AEterna Zentaris stated, "Cetrotide ... ... Pay-Per-View - PR Newswire - HighBeam Research Pharma Blog Watch - Nov 29, 2007 Judith Layzer has been taking Cetrotide, a fertility treatment, since 1999 to fight ... Upon her retirement, Medicare Part D denied coverage of Cetrotide. ... FDA news - FDA news (subscription) AEterna's 3rd qtr loss quadruples on costs.(AEterna Zentaris)(Financia... - Nov 19, 2007 The higher development expenditure was largely a result of costs incurred due to ongoing Phase III trials of AEterna's drug Cetrotide (cetrolix) in the ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Actualités en bref Vol 8 no.30 — Sciences de la vie — Le 21 novembre ... - Nov 21, 2008 De plus, AEterna Zentaris pourrait toucher une somme additionnelle de 2,5 M$ de CHRP, advenant le cas où les ventes nettes de Cetrotide(MD) en 2010 ... ic.gc.ca Press Release: AEterna Zentaris Enters a License and Collaboration … - Aug 3, 2006 Article: AEterna Zentaris Launches Cetrotide(R) (cetrorelix) ... PR Newswire; September 21, 2006 ; 700+ words ... ... by partners Nippon Kayaku Co., Ltd .. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming Bio Contact in... - Sep 28, 2005 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris Reports Third Quarter 2007 Financial ... - Nov 7, 2007 The sales of Cetrotide(R) were lower for the three-month period ended September 30, 2007 compared to the same period in 2006, due to a significant first ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming Bio Investor … - Oct 13, 2005 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming Rodman & … - May 15, 2008 Executive Officer at AEterna Zentaris. Dr. Jurgen Engel, Executive Vice President Global R&D ... Operating Officer at AEterna Zentaris stated, "Cetrotide . ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris appoints a Board Vice Chairman, a New... - Nov 21, 2005 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming BMO Capital … - Jul 31, 2008 Executive Officer at AEterna Zentaris. Dr. Jurgen Engel, Executive Vice President Global R&D ... Operating Officer at AEterna Zentaris stated, "Cetrotide . ... Pay-Per-View - PR Newswire - HighBeam Research cetrorelix AEterna Zentaris marketed, Japan (infertility).(Nippon... - Oct 2, 2006 On 21 September 2006 AEterna Zentaris reported that its partners Nippon Kayaku and Shionogi have launched cetrorelix (CETROTIDE) in Japan for in vitro ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Press Release: AEterna Zentaris to Present at Upcoming CIBC World … - Sep 15, 2005 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Article: High-tech child's play; Soon, experts say, the real thing... - Nov 16, 2005 Two marketed products are gaining market share; Cetrotide ... 2003, growing revenues from our marketed products, and a strong performance from Atrium ... Pay-Per-View - Christian Science Monitor - HighBeam Research Aeterna Zentaris creuse encore sa perte - Nov 7, 2007 Ce recul, par rapport au troisième trimestre de 2006, s'explique par la forte commande initiale de Cetrotide liée à son lancement sur le marché japonais en ... Le Journal de Québec Actualités en bref Vol 8 no.33 — Sciences de la vie — Le 12 décembre ... - Dec 12, 2008 ...droits d'AEterna Zentaris sur les redevances découlant des ventes futures de Cetrotide(MD) faisant partie de son contrat de licence avec Merck Serono. ... ic.gc.ca Infertility in Women Medications - Infertility in Women Health... - Oct 29, 2007 GnRH antagonists include ganirelix (Antagon) and cetrorelix (Cetrotide). GnRH antagonists suppress FSH and LH more than GnRH agonists, and they may require ... New York Times CANADA STOCKS-Toronto index set to slip on oil drop - Nov 12, 2008 TO) has agreed to sell its Cetrotide royalty stream for $52.5 million to Cowen Healthcare Royalty Partners. [ID:nWNAB2199]. GeneNews Ltd (GEN. ... Reuters Press Release: AEterna Zentaris Strategic Shareholder, The Solidarity... - Feb 15, 2006 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming Canaccord … - May 25, 2006 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Spectrum Pharmaceuticals Announces a License and … - Aug 3, 2006 Article: AEterna Zentaris Launches Cetrotide(R) (cetrorelix) ... PR Newswire; September 21, 2006 ; 700+ words ... ... by partners Nippon Kayaku Co., Ltd .. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at the Upcoming Roth... - Feb 19, 2008 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming CIBC World … - Apr 5, 2007 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris In. Review in Progress. - M2 Presswire... - Apr 11, 2008 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: AEterna Zentaris Sells Quebec City Building for $7.1 … - Jun 27, 2008 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Webcast Analyst Meeting in Toronto... - Nov 27, 2006 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris to Present at Upcoming Acumen BioFin ... - May 9, 2007 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Progressive Review for AEterna Zentaris Inc. - M2 … - Mar 3, 2008 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: AEterna Zentaris Inc. Under Review. - M2 Presswire | … - Mar 28, 2007 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: AEterna Zentaris to Present First In Vivo Data on... - Oct 19, 2006 Article: AEterna Zentaris Gets $52.5M from Cetrotide Royalty ... BIOWORLD Today; November 13, 2008 ; 700+ words ... ... subsidiary during the past year, ... Pay-Per-View - PR Newswire - HighBeam Research Serono falls as buyers fail to materalizeMOVERSMARKETPLACE by … - Jan 25, 2006 Serono's fastest-growing products are the psoriasis medicine Raptiva, the ovulation hormone Ovidrel, the ovulation control hormone Cetrotide, ... Pay-Per-View - International Herald Tribune - HighBeam Research Gonadotropin-releasing hormone analogues for infertility - Mar 21, 2008 Cetrotide is injected under the skin 1 time daily for several days, or 1 time on day 7 of the menstrual cycle. Antagon is injected under the skin 1 time ... WebMD Is There Still Hope After 40? - Aug 24, 2005 ...an oral contraceptive/Lupron flare, and a gonadotropin-releasing hormone (GnRH) antagonist protocol, which included Cetrotide or Antagon. ... Fertility Neighborhood AEterna Zentaris Subsidiary Atrium Biotechnologies Files Final … - Mar 30, 2005 The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide(R). ... npicenter.com AEterna Zentaris' Partner Spectrum Granted IND From FDA to Conduct … - May 31, 2005 The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide(R). ... RedOrbit Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial ... - Mar 5, 2008 The increase in revenues for 2007 is mainly related to increased sales of Cetrotide® and Impavido®, partly compensated by lower license fees revenues from ... Lifescience-online Serono Announces Formal Conclusion of Serostim Settlement. - Dec 15, 2005 Crinone 8%(R) (progesterone gel), Cetrotide(R) (cetrorelix acetate for injection), Serostim(R) [somatropin (rDNA origin) for injection], ... Free with registration - PR Newswire - AccessMyLibrary.com AEterna Zentaris Initiates First Study of Phase 3 Program With... - Jan 8, 2007 Cetrorelix is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs ... RedOrbit AEterna Zentaris Announces Outcome of Management's Strategic Review … - Oct 2, 2007 The decision to proceed with development was made based on: a) the proven safety and efficacy of Cetrotide(R) b) the overall database from preclinical and ... Free with registration - PR Newswire - AccessMyLibrary.com AEterna Zentaris Completes Patient Recruitment for Safety Trial of... - Dec 11, 2008 Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization ... International Business Times AEterna Zentaris Completes Patient Recruitment for Second Efficacy... - Oct 1, 2008 Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization ... Genetic Engineering News - Genetic Engineering News (press release) AEterna Zentaris Reports First Patients Treated With Cetrorelix for... - Apr 19, 2007 Cetrorelix is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs ... RedOrbit Bold bets: Serono is muscling its way into the US market with head-to... - Jan 1, 2005 The unit's other products--Cetrotide (cetrorelix), Crinone (progesterone gel), Ovridrel (choriogonadotropin), and Luveris (lutropin alpha)--together ... Free with registration - Pharmaceutical Executive - AccessMyLibrary.com Serono Delivers Strong Adjusted* Net Income of $183.5m in Third... - Oct 19, 2006 Global sales of supporting products (Ovidrel(R), Cetrotide(R), Crinone(R) and Luveris(R)) were up 11.5%, or 9.5% in local currencies to $21.9m (Q3 2005: ... Free with registration - PR Newswire - AccessMyLibrary.com Can I Use Vaginal Progesterone During IVF? - Oct 13, 2008 Medications used to slow down premature ovulation (such as Lupron, Antagon or Cetrotide) may reduce the production of progesterone following collection of ... About.com - Drugs AEterna Zentaris Reports 2006 First Quarter Financial and Operating … - May 3, 2006 Recent Events - Gained market approval for Cetrotide(R) (cetrorelix) in Japan for in vitro fertilization. Gilles Gagnon, AEterna Zentaris' President and ... Free with registration - PR Newswire - AccessMyLibrary.com AEterna Zentaris Announces First Patient Dosing for Safety Trial of... - May 14, 2008 Cetrorelix acetate is marketed under the brand name Cetrotide®, the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization ... Lifescience-online Article : Analyst Likes AEterna Long-Term Genetic Engineering & … - Mar 15, 2006 Its lead LRHR antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide. ... Genetic Engineering News - Genetic Engineering News (press release) How to Deal with the High Cost of Fertility Meds - Nov 24, 2008 ..."Gonal-F Pen 900 IU $275 each, Gonal-F 75 IU $20 per vial, Follistim 900 IU $250, Cetrotide 0.25 mg $25. Buyer pays shipping". ... Fertility Neighborhood AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins... - Apr 30, 2008 Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization ... RedOrbit Infectious Diseases; Regulatory approval granted in Columbia for … - Apr 25, 2005 ..."With two products on the market generating revenues, Cetrotide and Impavido, we are further establishing a solid financial basis to support the development ... Pay-Per-View - Anti-Infectives Week - Factiva, from Dow Jones AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH. - Nov 29, 2006 Cetrorelix is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs ... $4.95 - PR Newswire - ECNext Finance; Neurology-focused biotechnology company reports strong full-... - Mar 1, 2005 Luveris) and 2 complementary products (Cetrotide, Crinone) grew by 8.5% to $645.6 million representing 93.3% of total reproductive health sales in 2004. ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Serono Delivers Second Quarter EPS of $12.92, Up 25.2% on Adjusted(1 … - Jul 26, 2006 Global sales of supporting products (Ovidrel(R), Cetrotide(R), Crinone(R) and Luveris(R)) were up 6.9%, or 7.5% in local currencies to $23.8m (Q2 2005: ... $4.95 - PR Newswire - ECNext AEterna Zentaris' North American Partner Announces Disclosure of … - May 16, 2005 The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide(R). ... $4.95 - PR Newswire - ECNext AEterna Zentaris Enters a License and Collaboration Agreement for … - Aug 3, 2006 ...our long-time partner Nippon Kayaku who has extensive expertise in drug development and currently prepares the market launch in Japan of Cetrotide(R), ... $4.95 - PR Newswire - ECNext Infectious Diseases; Regulatory approval granted in Columbia for … - Apr 30, 2005 ..."With two products on the market generating revenues, Cetrotide and Impavido, we are further establishing a solid financial basis to support the development ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Brand Names/Synonyms: Cetrotide is also known by the following brand names and/or synonymsCetrorelix; Cetrorelix Acetate; Cetrorelix [Inn]; Cetrorelixum [Inn-Latin]; Cetrotide; Cetyl Pyridinium Bromide; Cetyl Pyridinium Chloride; Cetyl Pyridinium Chloride for Synthesis; Cetylpyridinium Chloride Monohydrate; Chondroitin Hydrochloride; Hexadecyl Pyridinium Bromide; Hexadecylpyridinium Chloride Monohydrate; N-Cetylpyridinium Bromide; N-Hexadecylpyridinium Bromide; Pyrisept; SB-75 Drug Category: Cetrotide is categorized under the following by the FDA: Infertility Agents; Hormone Antagonists; ATC:H01CC02 Dosage Forms: POWDER FOR SOLUTION Absorption: Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%. Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |